Tempus AI Sees Unusually Large Options Volume (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) saw some unusual options trading activity on Thursday. Stock traders purchased 66,754 call options on the stock. This is an increase of 118% compared to the typical volume of 30,651 call options.

Insider Activity at Tempus AI

In other Tempus AI news, CEO Ryan Fukushima sold 41,095 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $2,038,722.95. Following the transaction, the chief executive officer directly owned 562,463 shares in the company, valued at $27,903,789.43. This represents a 6.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares of the company’s stock, valued at $7,246,383.87. This represents a 13.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,043,988 shares of company stock valued at $56,963,417 over the last 90 days. 24.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Amova Asset Management Americas Inc. lifted its position in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares during the last quarter. Norges Bank acquired a new position in shares of Tempus AI during the fourth quarter worth $48,234,000. Franklin Resources Inc. increased its position in shares of Tempus AI by 27.9% during the fourth quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock worth $109,938,000 after purchasing an additional 405,662 shares in the last quarter. Finally, Lingotto Investment Management LLP raised its stake in Tempus AI by 45.9% in the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock valued at $67,525,000 after buying an additional 359,667 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Up 14.5%

Shares of TEM traded up $10.15 during trading hours on Thursday, hitting $80.12. The company had a trading volume of 9,727,220 shares, compared to its average volume of 6,076,302. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $14.46 billion, a PE ratio of -55.49 and a beta of 3.72. Tempus AI has a one year low of $40.77 and a one year high of $104.32. The company’s fifty day moving average price is $56.42 and its two-hundred day moving average price is $52.53.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. As a group, equities analysts forecast that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of recent research reports. Raymond James Financial set a $80.00 price target on Tempus AI in a research report on Wednesday, September 2nd. Rothschild & Co Redburn began coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Friday, July 31st. HC Wainwright upped their price objective on shares of Tempus AI from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Finally, Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 11th. Eleven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $69.33.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.